pharma news today obesity drugs glp-1 today Agonists Weight Loss Market Report, 2025-2030 pharma news today glp-1 obesity

Large cardiovascular outcome trials (e.g., Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER), SUSTAIN) and post-marketing surveillance have not demonstrated an increased incidence of MTC in humans, though long-term pharmacovigilance continues given the rarity of this malignancy [30,62]

9-13 In two of the trials, there was a significant association between the use of a synthetic GLP-1/GIP agonist and worse eye-related outcomes

& Zhou, B

Finally, legislative support should promote equitable access to these agents, especially for vulnerable and underrepresented patient populations who also carry the highest burden of CVD and CKD risk with T2D

This active ingredient has become the leading drug in its class due to its proven safety and efficacy

Further clinical evidence is needed to verify the effects of GLP-1R agonists on cognitive function and pathology in AD patients